ETF Holdings Breakdown of INSM

News associated with INSM

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein Sells 57,765 Shares

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,765 shares of the stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $101.78, for a total value of $5,879,321.70. Following the completion of the sale, the chief financial officer now owns 93,536 shares in the […] - 2025-06-27 08:06:55

Avior Wealth Management LLC Raises Holdings in Insmed, Inc. (NASDAQ:INSM)

Avior Wealth Management LLC lifted its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 82.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 4,151 shares of the biopharmaceutical company’s stock after acquiring an additional 1,873 shares during the period. Avior Wealth Management LLC’s holdings […] - 2025-06-23 08:12:58

Is Insmed Stock Overvalued at $98?

Insmed Inc (NASDAQ: INSM) was nothing short of a juggernaut last month, skyrocketing 45%, while the S&P500 index gained 3% during the same period. What’s fueling the fire? Insmed announced that its Phase IIb trial for treprostinil palmitil inhalation powder (TPIP) in pulmonar - 2025-06-17 06:35:22

Notable ETF Outflow Detected - IWO, SFM, INSM, FTAI

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected an approximate $123.7 million dollar outflow -- that's a 1.1% decrease week ove - 2025-06-16 14:49:52

Insmed Incorporated (NASDAQ:INSM) CFO Sells $5,148,105.92 in Stock

Insmed Incorporated (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,766 shares of the company’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total transaction of $5,148,105.92. Following the sale, the chief financial officer now directly owns 103,412 shares in the company, […] - 2025-06-16 08:18:57

Park Avenue Securities LLC Has $842,000 Holdings in Insmed Incorporated (NASDAQ:INSM)

Park Avenue Securities LLC boosted its position in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 38.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 11,036 shares of the biopharmaceutical company’s stock after purchasing an additional 3,081 shares during the quarter. Park Avenue Securities LLC’s holdings in Insmed were worth $842,000 […] - 2025-06-13 08:18:50

Morgan Stanley Increases Insmed (NASDAQ:INSM) Price Target to $102.00

Insmed (NASDAQ:INSM – Get Free Report) had its price objective lifted by stock analysts at Morgan Stanley from $90.00 to $102.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 5.28% from the stock’s previous close. […] - 2025-06-13 07:40:52

Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says

Insmed (NASDAQ:INSM – Get Free Report) had its target price raised by research analysts at Royal Bank of Canada from $99.00 to $106.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 9.41% […] - 2025-06-13 07:40:51

Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Mizuho Analyst Says

Insmed (NASDAQ:INSM – Get Free Report) had its price objective lifted by equities research analysts at Mizuho from $96.00 to $110.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 13.54% from the company’s current price. […] - 2025-06-13 07:40:49

Insmed (NASDAQ:INSM) Shares Up 4.5% Following Analyst Upgrade

Insmed Incorporated (NASDAQ:INSM – Get Free Report)’s stock price traded up 4.5% during trading on Wednesday after The Goldman Sachs Group raised their price target on the stock from $100.00 to $112.00. The Goldman Sachs Group currently has a buy rating on the stock. Insmed traded as high as $93.82 and last traded at $95.02. […] - 2025-06-13 05:17:01

INSM Crosses Above Average Analyst Target

In recent trading, shares of Insmed Inc (Symbol: INSM) have crossed above the average analyst 12-month target price of $97.70, changing hands for $97.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation - 2025-06-12 11:33:46

Bank of America Increases Insmed (NASDAQ:INSM) Price Target to $109.00

Insmed (NASDAQ:INSM – Free Report) had its price objective boosted by Bank of America from $94.00 to $109.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on INSM. Stifel Nicolaus reduced their target price […] - 2025-06-12 08:08:53

Wells Fargo & Company Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM – Free Report) had its target price upped by Wells Fargo & Company from $107.00 to $119.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on INSM. Stifel Nicolaus decreased […] - 2025-06-12 07:32:54

Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Leerink Partners Analyst Says

Insmed (NASDAQ:INSM – Get Free Report) had its price objective raised by research analysts at Leerink Partners from $100.00 to $115.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners’ target price suggests a potential upside of 17.37% from the stock’s previous […] - 2025-06-12 05:54:53

Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr

(RTTNews) - Insmed Inc. (INSM) announced that it priced an underwritten public offering of about 7.81 million shares of its common stock at a price to the public of $96.00 per share. - 2025-06-12 03:20:24

Mackenzie Financial Corp Grows Stake in Insmed Incorporated (NASDAQ:INSM)

Mackenzie Financial Corp lifted its stake in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 12.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,883 shares of the biopharmaceutical company’s stock after buying an additional 1,213 shares during the period. Mackenzie Financial Corp’s […] - 2025-06-02 08:49:01

Insmed (NASDAQ:INSM) Earns “Buy” Rating from HC Wainwright

Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $90.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 36.97% from the company’s previous close. A […] - 2025-05-14 06:12:47

Notable ETF Inflow Detected - VTWO, INSM, FTAI, CORT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 2000 (Symbol: VTWO) where we have detected an approximate $654.2 million dollar inflow -- that's a 6.1% increase week over week in o - 2025-05-07 14:54:13

Renaissance Technologies LLC Buys New Shares in Insmed Incorporated (NASDAQ:INSM)

Renaissance Technologies LLC bought a new stake in Insmed Incorporated (NASDAQ:INSM – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 25,287 shares of the biopharmaceutical company’s stock, valued at approximately $1,746,000. Other institutional investors have also recently added to or reduced […] - 2025-04-28 07:44:58

Cerity Partners LLC Sells 3,090 Shares of Insmed Incorporated (NASDAQ:INSM)

Cerity Partners LLC decreased its holdings in Insmed Incorporated (NASDAQ:INSM – Free Report) by 14.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,258 shares of the biopharmaceutical company’s stock after selling 3,090 shares during the quarter. Cerity Partners LLC’s holdings […] - 2025-04-18 08:06:53

Envestnet Asset Management Inc. Increases Stake in Insmed Incorporated (NASDAQ:INSM)

Envestnet Asset Management Inc. grew its position in Insmed Incorporated (NASDAQ:INSM – Free Report) by 6.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 256,358 shares of the biopharmaceutical company’s stock after purchasing an additional 15,227 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Insmed were worth $17,699,000 as of […] - 2025-04-16 07:56:51

Wells Fargo & Company MN Boosts Position in Insmed Incorporated (NASDAQ:INSM)

Wells Fargo & Company MN lifted its position in Insmed Incorporated (NASDAQ:INSM – Free Report) by 26.1% during the 4th quarter, HoldingsChannel reports. The firm owned 160,709 shares of the biopharmaceutical company’s stock after buying an additional 33,214 shares during the period. Wells Fargo & Company MN’s holdings in Insmed were worth $11,095,000 at the […] - 2025-04-16 07:24:55

IWM, SFM, INSM, FTAI: ETF Inflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 ETF (Symbol: IWM) where we have detected an approximate $718.7 million dollar inflow -- that's a 1.2% increase week over week in - 2025-04-15 15:02:26

Corient Private Wealth LLC Has $1.02 Million Position in Insmed Incorporated (NASDAQ:INSM)

Corient Private Wealth LLC lifted its stake in Insmed Incorporated (NASDAQ:INSM – Free Report) by 34.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,730 shares of the biopharmaceutical company’s stock after acquiring an additional 3,747 shares during the quarter. Corient Private Wealth LLC’s […] - 2025-03-27 08:50:53

Envestnet Portfolio Solutions Inc. Increases Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Envestnet Portfolio Solutions Inc. increased its position in Insmed Incorporated (NASDAQ:INSM – Free Report) by 3.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,314 shares of the biopharmaceutical company’s stock after acquiring an additional 225 shares during the quarter. Envestnet Portfolio Solutions Inc.’s […] - 2025-03-27 08:04:55

Analysts Set Insmed Incorporated (NASDAQ:INSM) Target Price at $94.00

Insmed Incorporated (NASDAQ:INSM – Get Free Report) has been given a consensus recommendation of “Buy” by the sixteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the […] - 2025-03-26 05:52:54

Xponance Inc. Grows Stock Position in Insmed Incorporated (NASDAQ:INSM)

Xponance Inc. grew its position in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 23.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 12,689 shares of the biopharmaceutical company’s stock after purchasing an additional 2,380 shares during the quarter. Xponance Inc.’s holdings in Insmed were worth $876,000 as of its most […] - 2025-03-25 08:37:04

Royal Bank of Canada Reiterates Outperform Rating for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $100.00 target price on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target points to a potential upside […] - 2025-03-21 06:42:57

26,995 Shares in Insmed Incorporated (NASDAQ:INSM) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new stake in Insmed Incorporated (NASDAQ:INSM – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,995 shares of the biopharmaceutical company’s stock, valued at approximately $1,864,000. A number of other […] - 2025-03-20 09:04:51

Victory Capital Management Inc. Trims Stake in Insmed Incorporated (NASDAQ:INSM)

Victory Capital Management Inc. reduced its stake in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 10.0% in the 4th quarter, Holdings Channel reports. The fund owned 410,577 shares of the biopharmaceutical company’s stock after selling 45,382 shares during the period. Victory Capital Management Inc.’s holdings in Insmed were worth $28,346,000 as of its […] - 2025-03-11 08:15:01

INSM institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	114,690	USD 11,668,561
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	64,298	USD 6,541,679
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	90,890	USD 9,247,149
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	90,890	USD 9,247,149
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	2,432	USD 247,432
Total =		363,200	USD 36,951,970

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer